# Kurome Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kurome-therapeutics

- Industry: Biotechnology
- Headquarters: Cincinnati, US
- Website: www.kurometherapeutics.com
- Total disclosed funding: $15M
- Latest round: Series A (Jun 10, 2021)
- Investors on record: 3

## About

Based in Ohio, US, and founded in 2019, Kurome Therapeutics operates as a pre-clinical stage company that focuses on developing targeted kinase inhibitors for patients with hematological cancers. The company was co-founded by Jan Rosenbaum and John Rice and is backed by Series A investors Affinity Asset Advisors, CincyTech, and Medicxi Ventures in June 2021.

Kurome Therapeutics develops a series of IRAK-4 (interleukin-1 receptor-associated kinase 4) and panFLT3 inhibitors to target adaptive resistance mechanisms in cancer cells. The company also helps to improve the outcome of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Kurome Therapeutics plans to use the funding to support the pre-clinical advancement of dual IRAK1/4 and panFLT3 inhibitors.

## Funding rounds

- Series A, Jun 10, 2021, $15M — CincyTech, Medicxi, Affinity Asset Advisors
- Seed, Apr 29, 2020 — CincyTech

## Investors

- CincyTech (https://capitalatlas.ai/funds/cincytech) — Seed, Series A
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series A
- Affinity Asset Advisors (https://capitalatlas.ai/funds/affinity-asset-advisors) — Series A